Swiss National Bank’s MoonLake Immunotherapeutics MLTX Stock Holding History

Swiss National Bank’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.7M	Buy	87,100 +25,600	+42%	+$464K	﹤0.01%	2017
2026 Q1	$1.15M	Hold	61,500	–	–	﹤0.01%	2104
2025 Q4	$811K	Buy	61,500 +18,500	+43%	+$218K	﹤0.01%	2233
2025 Q3	$308K	Buy	43,000 +700	+2%	+$36.5K	﹤0.01%	2313
2025 Q2	$2M	Sell	42,300 -700	-2%	-$28.5K	﹤0.01%	1813
2025 Q1	$1.68M	Hold	43,000	–	–	﹤0.01%	1871
2024 Q4	$2.33M	Hold	43,000	–	–	﹤0.01%	1762
2024 Q3	$2.17M	Buy	43,000 +12,100	+39%	+$567K	﹤0.01%	1816
2024 Q2	$1.36M	Sell	30,900 -4,400	-12%	-$186K	﹤0.01%	2011
2024 Q1	$1.77M	Hold	35,300	–	–	﹤0.01%	1907
2023 Q4	$2.13M	Sell	35,300 -4,500	-11%	-$232K	﹤0.01%	1789
2023 Q3	$2.27M	Buy	+39,800	New	+$2.2M	﹤0.01%	1752

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Swiss National Bank's MLTX Position: Q2 2026 in Review

Swiss National Bank increased its MoonLake Immunotherapeutics (MLTX) stake by 42% in Q2 2026, buying an estimated $464K and bringing the position to 87,100 shares worth $1.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2017.

Swiss National Bank first reported a position in MLTX in Q3 2023 and has held it in 12 quarters since. The position peaked at $2.33M in Q4 2024. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Swiss National Bank held 87,100 shares of MoonLake Immunotherapeutics worth $1.7M as of Q2 2026.
Swiss National Bank bought 25,600 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $464K.
MoonLake Immunotherapeutics made up ﹤0.01% of Swiss National Bank's portfolio in Q2 2026, its #2017 holding.
Swiss National Bank first reported a position in MoonLake Immunotherapeutics in Q3 2023 and has held it in 12 quarters since.
Swiss National Bank's MoonLake Immunotherapeutics position peaked at $2.33M in Q4 2024.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.